LLY

1,023.98

-2.1%↓

JNJ

238.23

-0.2%↓

ABBV

222.29

-0.37%↓

NVS

158.25

+0.92%↑

MRK

117.15

-0.43%↓

LLY

1,023.98

-2.1%↓

JNJ

238.23

-0.2%↓

ABBV

222.29

-0.37%↓

NVS

158.25

+0.92%↑

MRK

117.15

-0.43%↓

LLY

1,023.98

-2.1%↓

JNJ

238.23

-0.2%↓

ABBV

222.29

-0.37%↓

NVS

158.25

+0.92%↑

MRK

117.15

-0.43%↓

LLY

1,023.98

-2.1%↓

JNJ

238.23

-0.2%↓

ABBV

222.29

-0.37%↓

NVS

158.25

+0.92%↑

MRK

117.15

-0.43%↓

LLY

1,023.98

-2.1%↓

JNJ

238.23

-0.2%↓

ABBV

222.29

-0.37%↓

NVS

158.25

+0.92%↑

MRK

117.15

-0.43%↓

Search

Novocure Ltd

Chiusa

SettoreSettore sanitario

10.46 4.29

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

10.03

Massimo

10.61

Metriche Chiave

By Trading Economics

Entrata

2.9M

-37M

Vendite

8.4M

167M

EPS

-0.33

Margine di Profitto

-22.29

Dipendenti

1,488

EBITDA

9.7M

-26M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+135.09% upside

Dividendi

By Dow Jones

Utili prossimi

26 feb 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-395M

1.1B

Apertura precedente

6.17

Chiusura precedente

10.46

Notizie sul Sentiment di mercato

By Acuity

100%

0%

336 / 352 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

Novocure Ltd Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

10 feb 2026, 23:26 UTC

I principali Market Mover

Moderna Stock Slips After FDA Refuses Flu Vaccine Review

10 feb 2026, 22:31 UTC

Utili

Correction to America Movil 4Q Profit Article

10 feb 2026, 22:22 UTC

Utili

America Movil 4Q Profit Jumps on Lower Financial Costs

10 feb 2026, 23:51 UTC

Discorsi di Mercato
Utili

Commonwealth Bank's Margin Management Gives It a Platform -- Market Talk

10 feb 2026, 23:42 UTC

Discorsi di Mercato

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

10 feb 2026, 23:40 UTC

Discorsi di Mercato
Utili

Commonwealth Bank Bear Says 1H Result Looks Strong -- Market Talk

10 feb 2026, 23:21 UTC

Discorsi di Mercato

Ford Says EV Shift Was Driven by Demand Changes -- Market Talk

10 feb 2026, 23:21 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

10 feb 2026, 22:17 UTC

Discorsi di Mercato

Australia's One Nation Now Commands Working Class Vote -- Market Talk

10 feb 2026, 22:15 UTC

Utili

Humana Earnings Will Shed More Light on Medicare Prospects -- Barrons.com

10 feb 2026, 22:10 UTC

Utili

Intact Financial 4Q Book Value Per Share Was C$107.35 >IFC.T

10 feb 2026, 22:10 UTC

Utili

Intact Financial Raises Qtr Dividend to C$1.47 >IFC.T

10 feb 2026, 22:09 UTC

Utili

Intact Financial 4Q Combined Ratio Was 85.9% >IFC.T

10 feb 2026, 22:09 UTC

Utili

Intact Financial 4Q Adj EPS C$5.50 >IFC.T

10 feb 2026, 22:01 UTC

Utili

Intact Financial 4Q EPS C$5.24 >IFC.T

10 feb 2026, 21:54 UTC

Utili

James Hardie Industries Sees FY26 Total Adjusted EBITDA $1.232B to $1.263B >JHX

10 feb 2026, 21:53 UTC

Utili

Robinhood Stock Tumbles as Crypto-Related Revenue Falls Short of Expectations -- Barrons.com

10 feb 2026, 21:51 UTC

Utili

James Hardie Industries Sees FY26 Free Cash Flow at Least $200M

10 feb 2026, 21:51 UTC

Utili

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

10 feb 2026, 21:51 UTC

Utili

James Hardie Industries: Focused on the Achievement of $125 M Target >JHX

10 feb 2026, 21:51 UTC

Utili

James Hardie Industries: Integration and Cost Synergies Ahead of Schedule >JHX

10 feb 2026, 21:51 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Evolution Net Debt A$362 Million at Dec. 31 Vs A$1.29 Billion Year Earlier

10 feb 2026, 21:50 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Evolution: Gearing 6% at Dec. 31, From 23% a Year Earlier

10 feb 2026, 21:50 UTC

Utili

James Hardie Industries 3Q EPS 12c >JHX

10 feb 2026, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

10 feb 2026, 21:50 UTC

Utili

James Hardie Industries 3Q Adj EPS 24c >JHX

10 feb 2026, 21:49 UTC

Utili

James Hardie Industries 3Q Sales $1.24B >JHX

10 feb 2026, 21:49 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Evolution 1H Operating Mine Cash Flow a Record A$1.73 Billion

10 feb 2026, 21:48 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Evolution 1H Ebitda A$1.56 Billion, Up 59% On-Year

10 feb 2026, 21:47 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Evolution 1H Revenue A$2.79 Billion, Up 37% On-Year

Confronto tra pari

Modifica del prezzo

Novocure Ltd Previsione

Obiettivo di Prezzo

By TipRanks

135.09% in crescita

Previsioni per 12 mesi

Media 23.58 USD  135.09%

Alto 39 USD

Basso 13.5 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Novocure Ltd - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

6 ratings

4

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

16.31 / 18.14Supporto e resistenza

A breve termine

Bearish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bearish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Novocure Ltd

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
help-icon Live chat